Biopharmaceutics & Drug disPosition

Papers
(The median citation count of Biopharmaceutics & Drug disPosition is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
53
In situ evaluation of the impact of metformin or verapamil coadministration with vildagliptin on its regional absorption from the rabbit’s intestine43
Aging and brain free cholesterol concentration on amyloid‐β peptide accumulation in guinea pigs32
Evaluation of bottom‐up modeling of the blood–brain barrier to improve brain penetration prediction via physiologically based pharmacokinetic modeling23
Issue Information21
20
Self‐micellizing solid dispersion of tacrolimus: Physicochemical and pharmacokinetic characterization19
Evaluating gender effect in the generic bioequivalence studies by physiologically based pharmacokinetic modeling – A case study of dextromethorphan modified release tablets14
Issue Information14
Issue Information13
Issue Information12
Evidence for cytochrome P450 3A4‐mediated metabolic activation of SCO‐26711
Attenuation of phenobarbital‐induced cytochrome P450 expression in carbon tetrachloride‐induced hepatitis in mice models11
Issue Information11
Utility of cystatin C and serum creatinine‐based glomerular filtration rate equations in predicting vancomycin clearance: A population pharmacokinetics analysis in elderly Chinese patients11
Estimation of fraction of drug metabolism by a single UDP‐glucuronosyl transferase enzyme using relative expression factor10
Ampicillin Is a Substrate of Organic Anion Transporters 39
Novel Enteric Microsphere of Beclomethasone Dipropionate With Colon Delivery and Enhancement of Anti‐Inflammatory Effects9
Metabolism and pharmacokinetic study of deuterated osimertinib9
Issue Information9
Irinotecan‐induced gastrointestinal damage alters the expression of peptide transporter 1 and absorption of cephalexin in rats8
Enhanced Vatiquinone Bioavailability With Fatty Meals and Optimal Dosing Schedule8
Pharmacokinetic control of orally dosed cyclosporine A with mucosal drug delivery system6
Integration of artificial neural network and physiologically based biopharmaceutic models in the development of sustained‐release formulations6
Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study6
Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells6
Intestinal absorption pathways of lisinopril: Mechanistic investigations6
The Role of Nasal Drug Delivery in Migraine Management and Brain‐Targeted Therapy: Insights From Taiwan6
Species Differences in Carboxylesterases Among Humans, Cynomolgus Monkeys, and Mice in the Hydrolysis of Atorvastatin Derivatives6
6
Predicting transporter mediated drug–drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward5
Pharmacokinetic Studies of a Novel c‐Met Targeting PROTAC Drug Candidate Using UPLC‐MS/MS Quantification Methods5
Prediction of basic drug exposure in milk using a lactation model algorithm integrated within a physiologically based pharmacokinetic model4
Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds4
Comparative Study on Cannabidiol‐Loaded Solubilizing Systems for Improvement of Oral Bioavailability: Liposome and Cyclodextrin‐Based Formulations4
Issue Information4
Involvement of SLC16A1/MCT1 and SLC16A3/MCT4 in l‐lactate transport in the hepatocellular carcinoma cell line4
Contribution of Organic Anion Transporter 3 in Delayed Elimination of Methotrexate by Concomitant Administration of Febuxostat4
Identification and characterization of an endogenous biomarker of the renal vectorial transport (OCT2‐MATE1)4
Metabolism of testosterone and progesterone by cytochrome P450 2C19 allelic variants3
3
In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose‐to‐brain drug delivery3
3
Icaritin exhibits potential drug–drug interactions through the inhibition of human UDP‐glucuronosyltransferase in vitro3
Issue Information3
3
Characterization of AST‐001 non‐clinical pharmacokinetics: A novel selective AKR1C3‐activated prodrug in mice, rats, and cynomolgus monkeys2
Across‐Species Meta‐Analysis of Betamethasone Pharmacokinetics Utilizing a Minimal PBPK Model2
Pregnenolone Sulfate Permeation at the Blood–Brain Barrier is Independent of OATP2B1—In Vivo and In Vitro Insights2
In vivo monitoring of brain pharmacokinetics and pharmacodynamics with cerebral open flow microperfusion2
2
Prediction of Human Serum Concentration–Time Profiles of Golimumab and Ustekinumab Using Pharmacokinetic Data From Common Marmosets With Assessment of Anti‐Drug Antibodies2
Gender difference in the pharmacokinetics and metabolism of VX‐548 in rats2
Vector‐Based Comparison and Average Slope Can Refine Bioequivalence Claims: A Machine and Deep Learning Approach2
Nose to Brain Delivery of Curcumin Loaded Therapeutic Nanostructures for Neurodegenerative Diseases2
2
2
Transition of average drug‐to‐antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography‐tandem mass spectrometry2
Physiologically based pharmacokinetic model to predict drug concentrations of breast cancer resistance protein substrates in milk2
Issue Information1
An Optimised Mobilenet V2 Attention Parallel Network for Predicting Drug–Drug Interactions Through Combining Local and Global Features1
The Effect of α ‐Mangostin on the Pharmacokinetic Profile of Tofacitinib in Rats Both In Vitro and In Vivo1
Quantitative analysis of the impact of membrane permeability on intestinal first‐pass metabolism of CYP3A substrates1
Model‐informed drug development: The mechanistic HSK3486 physiologically based pharmacokinetic model informing dose decisions in clinical trials of specific populations1
1
Issue Information1
Optimized GFR Estimation Equations for Chinese Neonates and Children: Development of New Models and Comparison With Existing Ones1
Effect of hepar‐protecting Wuzhi capsule on pharmacokinetics and dose‐effect character of tacrolimus in healthy volunteers1
Issue Information1
Evaluation of bleeding and anticoagulation markers by edoxaban and low‐dose cyclosporine: A case series study1
Pharmacokinetic–pharmacodynamic modeling of the active components of Shenkang injection in rats with chronic renal failure and its protective effect on damaged renal cells1
A Slowly Self‐Emulsifying Delivery System of Sesamin With Improved Biopharmaceutical Properties1
1
The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery1
0.11756610870361